Cinda biology and San Nuo reach a strategic cooperation to carry out clinical research of cindilimab combined with RNAi therapy

Suzhou, January 8, 2020 / Meitong news agency / -- Xinda biopharmaceutical (stock code of Hong Kong Stock Exchange: 01801), a world-class biopharmaceutical company dedicated to R & D, production and sales of innovative drugs for the treatment of major diseases such as tumor, autoimmune, metabolic diseases, etc., and Sinopharm, a company dedicated to the application of RNA interference Technology (RNAi) in R & D and creation of anti-tumor and fibrotic diseases Today, the leading biopharmaceutical company of new drugs jointly announced that: the two companies have reached a strategic cooperation in clinical research, and jointly carried out clinical research in the United States on the treatment of tumors (such as HCC and cholangiocarcinoma) by using the PD-1 antibody drug of Cinda biopharmaceutical (injection of cindilimab) and the RNAi candidate drug stp705 (injection of corranine) Dr Zhou Hui, vice president of medical science and strategic Oncology Department of Cinda biopharmaceutical group, said: "cindilimab has been approved for marketing in China and has become the only anti-PD-1 monoclonal antibody drug listed in the national medical insurance catalog Because of its safety and effectiveness, cindilimab has been widely recognized At the same time, we are also in-depth exploration of the efficacy of cindilimab in combination therapy A number of clinical trials showed that the combination therapy of cindilimab was effective in the treatment of tumor We hope to evaluate the potential clinical value of the combination therapy of cindilimab and RNAi, so as to provide more comprehensive and effective treatment options for patients and benefit more patients " Dr Lu Yang, President and CEO of Sinopharm, said: "the cooperation between Sinopharm and Cinda biopharmaceuticals is the first exploration to combine RNAi candidate drugs with antibody drugs of immune checkpoints that have been put on the market for the treatment of liver cancer In fatal diseases such as liver cancer, it has been found that overexpression of some drug targets can hinder the infiltration of immune T cells and reduce their activity If these targets are silenced effectively, it is possible to promote the infiltration of immunot cells in tumor microenvironment and enhance the antitumor activity of immunocheckpoint inhibitors We can foresee that the combination of RNAi drugs and immunosuppressive agents is likely to provide more effective treatment for these diseases " Michael Molyneaux, MD, chief medical officer of Sinopharm, said: "Sinopharm is pleased to reach a strategic cooperation with Cinda biopharmaceuticals As we all know, although the treatment of liver cancer has made some progress in recent years, there are still huge unmet clinical needs The results of preclinical studies show that stp705 has a certain antitumor activity in liver cancer, and further mechanism studies also release a strong signal: the combination of stp705 and immunosuppressant may greatly benefit liver cancer patients Sinda biopharmaceutical has outstanding innovation ability and execution in clinical development, and has a common vision with us, committed to providing patients with life-saving treatment programs We believe that the combination of the new siRNA technology of Sinopharm and the cutting-edge antibody therapy of Cinda biopharmaceutical will significantly improve the current treatment of liver cancer patients " About Dabusu ® (cindilimab injection) Dabusu ® (cindilimab injection) is an innovative biological drug with international quality jointly developed by Cinda biopharmaceutical and Lilly pharmaceutical in China Its listing application has been officially approved by the State Drug Administration in 2018 The first indication approved is relapsed / refractory classic Hodgkin's lymphoma, and it has been selected into the 2019 China Society of Clinical Oncology (CSCO) lymphoma diagnosis and treatment guidelines Sindilimab injection became the only anti-PD-1 monoclonal antibody drug to enter the new national medical insurance catalogue in November 2019 Dabushu ® (sindilimab injection) is a monoclonal antibody against human immunoglobulin G4 (IgG4), which can specifically bind to the PD-1 molecule on the surface of T cells, thus blocking the PD-1 / programmed cell death-1 ligand-1 (programmed cell death-1 ligand-1) that leads to tumor immune tolerance, PD-L1) pathway can reactivate the antitumor activity of lymphocytes, so as to achieve the purpose of tumor treatment At present, more than 20 clinical studies (8 of which are registered clinical trials) are under way to explore the antitumor effect of sindilimab on other solid tumors At the same time, Cinda biology is carrying out clinical research of cindilimab injection in the United States Stp705, a leading candidate product of Sinopharm, is a RNAi therapeutic drug It uses double targeting inhibition and PNP to enhance the carrier, and directly knocks down the gene expression of TGF - β 1 and COX-2 The candidate product has been approved by the US FDA and China nmpa in a number of ind clinical trials, and can be used to treat cholangiocarcinoma, non melanoma skin cancer and hypertrophic scars Stp705 has also obtained the rare disease drug qualification granted by the US FDA to treat cholangiocarcinoma and primary sclerosing cholangitis In a series of preclinical studies, stp705 single drug has been proved to significantly improve the infiltration of immune T cells in liver cancer (HCC), and also improve the efficacy of PD-L1 antibody in liver cancer animal models This effect is believed to improve the efficacy of other immunosuppressive checkpoint inhibitors in addition to the effect on PD-1 / PD-L1 pathway Adorable adorable